
Quarterly report 2024-Q3
added 11-14-2024
Acutus Medical Revenue 2011-2025 | AFIB
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Acutus Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.16 M | 3.03 M | 17.3 M | 8.46 M | 2.84 M | 2.17 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.3 M | 2.17 M | 6.82 M |
Quarterly Revenue Acutus Medical
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.27 M | 4.13 M | 3.62 M | - | 2.06 M | 1.52 M | 1.24 M | - | 3.64 M | 4.08 M | 3.68 M | - | 4.6 M | 4.71 M | 3.59 M | - | 3.17 M | 1.13 M | 1.58 M | - | 646 K | 734 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.27 M | 646 K | 2.91 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abiomed
ABMD
|
848 M | - | - | $ 17.2 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Apyx Medical Corporation
APYX
|
52.3 M | $ 3.6 | - | $ 125 M | ||
|
Boston Scientific Corporation
BSX
|
16.7 B | $ 96.13 | 0.04 % | $ 141 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 301.75 | 0.24 % | $ 8.51 B | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 48.12 | 0.21 % | $ 7.17 K | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
Abbott Laboratories
ABT
|
42 B | $ 124.81 | 0.22 % | $ 217 B | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 2.97 | 4.58 % | $ 111 M | ||
|
InMode Ltd.
INMD
|
358 M | $ 14.47 | 0.7 % | $ 1.15 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Cognyte Software Ltd.
CGNT
|
443 M | $ 9.54 | - | $ 685 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Align Technology
ALGN
|
4 B | $ 157.84 | 0.69 % | $ 11.8 B | ||
|
NanoVibronix
NAOV
|
2.56 M | - | - | $ 1.08 M | ||
|
Accuray Incorporated
ARAY
|
459 M | $ 0.86 | 0.43 % | $ 88.4 M | ||
|
Myomo
MYO
|
1 B | $ 1.02 | 12.09 % | $ 7.19 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
31.4 M | $ 14.49 | 0.84 % | $ 392 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 14.53 | 0.07 % | $ 95.2 M | ||
|
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.14 | 3.64 % | $ 18.4 M | ||
|
IRadimed Corporation
IRMD
|
73.2 M | $ 97.06 | 0.48 % | $ 1.23 B | ||
|
AxoGen
AXGN
|
187 M | $ 32.64 | -0.61 % | $ 1.44 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
CONMED Corporation
CNMD
|
1.31 B | $ 40.17 | 1.34 % | $ 1.24 B | ||
|
OrthoPediatrics Corp.
KIDS
|
205 M | $ 17.41 | 0.75 % | $ 402 M | ||
|
Globus Medical
GMED
|
2.52 B | $ 88.43 | -0.38 % | $ 12 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 12.66 | 0.56 % | $ 975 M | ||
|
Aziyo Biologics
AZYO
|
24.7 M | - | 1.37 % | $ 20.5 M | ||
|
LivaNova PLC
LIVN
|
1.25 B | $ 63.08 | -0.27 % | $ 3.42 B | ||
|
Aethlon Medical
AEMD
|
574 K | $ 2.49 | -6.39 % | $ 3.89 M | ||
|
LENSAR
LNSR
|
53.5 M | $ 12.01 | -0.08 % | $ 138 M |